Drugs / VENT-03
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07260877 | Dec 2025 → Jul 2026 overdue | cutaneous lupus erythematosus, systemic lupus erythematosus | Ventus Therapeutics U.S., Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2024-10-31 | Ventus Therapeutics U.S., Inc. | Results Ventus Therapeutics Announces Successful Completion of Phase 1 Clinical Trial of VENT-03, a First-in-Class, Orally Administered cGAS Inhibitor ventustx.com ↗
In the Phase 1 trial, VENT-03 was safe and well-tolerated at doses far exceeding those planned for use in Phase 2 trials. |
| 2023-04-17 | Ventus Therapeutics U.S., Inc. | Results Ventus Therapeutics Provides Updates on cGAS Inhibitor Program at Keystone Symposium on Innate Immunity ventustx.com ↗
This presentation will mark the public debut of data showcasing the potency and pharmacokinetic profile of the company’s potential first-in-class cGAS inhibitor, VENT-03. |
All press releases naming this drug 7 releases
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VENT-03 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07260877 ↗ |